Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Arthur Sands, Nurix Therapeutics CEO June 8, 2026 06:57 AM EDTUpdated 07:25 AM DealsR&D Nurix to work with Roche on BTK de­grad­er in pact worth up to $2.3B Reynald Castaneda Deputy Editor Roche is set to pay Nurix Ther­a­peu­tics $700 mil­lion up­front to col­lab­o­rate on a BTK de­grad­er for B cell ma­lig­nan­cies, with … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER